H.C. Starck Divestment Finalized

Advent International and Carlyle Group completed their $1.56 billion (Euro 1.2 billion) acquisition of H.C. Starck from Bayer after receiving approval from U.S. and EU antitrust authorities. Bayer is using the proceeds from the sale to reduce net debt and fund its Schering acquisition. The new private equity owners hope that in 3-5 years they will be able to take the company public in an IPO.

Back to News